AstraZeneca mulls £7bn move for prostate cancer drug company Medivation

AstraZeneca mulls £7bn move for prostate cancer drug company Medivation

AstraZeneca is mulling a £7bn offer for the US drug company Medivation after it rejected a bid from a French rival. San Francisco-based Medivation, which has a best-selling prostate cancer treatment, has been on the radar of AstraZeneca and its rivals

(Visited 2 times, 1 visits today)
1
Like
Save

Comments

Write a comment

*